Melbourne-based ImmunoBiota Therapeutics aims to intervene earlier in the disease course of Type 1 diabetes by developing an oral treatment to modify the autoimmune mechanisms that drive the condition. …
Melbourne biotech pursues an oral path to changing Type 1 diabetes
August 14, 2026 Australian Biotech
Latest Video
New Stories
-
Pharmac aims to pivot toward faster process and broader value framework
August 17, 2026 - -
Has any patient ever said they accept a rejection because of the Kaplan-Meier curve?
August 17, 2026 - - Latest News -
Melbourne biotech pursues an oral path to changing Type 1 diabetes
August 14, 2026 - - Australian Biotech -
A plain language version of these dreadful and useless documents
August 14, 2026 - - Latest News -
An institution dominated by very clever people, but where is the wisdom?
August 14, 2026 - - Latest News -
CUREator+ backs six Australian startups with $13.5 million to advance new health technologies
August 13, 2026 - - Australian Biotech -
Medicines Australia appoints former AbbVie executive to key leadership role
August 13, 2026 - - Latest News